VANGUARD GROUP INC 13D and 13G filings for Revance Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:13 pm Purchase |
2023-12-29 | 13G | Revance Therapeutics, Inc. RVNC |
VANGUARD GROUP INC | 5,069,625 5.770% |
573,309 (+12.75%) |
Filing |
| 2023-02-09 11:30 am Purchase |
2022-12-30 | 13G | Revance Therapeutics, Inc. RVNC |
VANGUARD GROUP INC | 4,496,316 5.470% |
894,019 (+24.82%) |
Filing |
| 2022-02-10 08:32 am Purchase |
2021-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
VANGUARD GROUP INC | 3,602,297 5.020% |
3,602,297 (New Position) |
Filing |